India's Glenmark launches first oral antiviral drug FabiFlu to treat COVID-19 patients
New Delhi/IBNS: Amid the massive spike in number of cases, India-based pharmaceutical company 'Glenmark Pharmaceuticals' has launched antiviral drug Favipiravir, to be sold under the brand name FabiFlu, for the treatment of patients having mild to moderate COVID-19 symptoms.
The company received manufacturing and marketing rights after getting approval from the Drugs Controller General of India (DCGI) on Friday.
FabiFlu is the first oral Favipiravir-approved medication for the treatment of COVID-19.
During clinical trials, the medicine has produced up to 88% improvement in mild to moderate coronavirus patients.
-INDIAN 🇮🇳 Company GLENMARK gets the nod for Manufacturing & Marketing of FAVIPIRAVIR under the brand name FABIFLU to treat #COVID Mild & Moderate Patients.
— Dr. Navi 🇮🇳 🥼 (@DoctorPositive1) June 20, 2020
-34 tabs at ₹3500.
-Will be made available at 🥠& chemist shops.
-Will be sold under medical prescription.#coronavirus pic.twitter.com/sZFM3XCjjj
It will be available across the country by early next week, the company said on Saturday.
A pack of 34 oral tablets of 200 mg each will be sold at a cost of Rs 3,500 and the cost of the 14-day treatment will be an estimated Rs 14,000.
“This approval comes at a time when Covid-19 cases in India are spiralling like never before, putting tremendous pressure on our healthcare system,” Glenmark Pharmaceuticals Chairman and Managing Director Glenn Saldanha said.
India has so far registered over 4 lakhs cases of the highly contagious virus including 12,000 deaths.
Support Our Journalism
We cannot do without you.. your contribution supports unbiased journalism
IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.
Support objective journalism for a small contribution.
